<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958552-A1" country="EP" doc-number="2958552" kind="A1" date="20151230" family-id="47722142" file-reference-id="311201" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160454126" ucid="EP-2958552-A1"><document-id><country>EP</country><doc-number>2958552</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14705162-A" is-representative="NO"><document-id mxw-id="PAPP193871220" load-source="docdb" format="epo"><country>EP</country><doc-number>14705162</doc-number><kind>A</kind><date>20140218</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193871221" load-source="patent-office" format="original"><country>EP</country><doc-number>14705162.7</doc-number><date>20140218</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162029849" ucid="EP-13155741-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>13155741</doc-number><kind>A</kind><date>20130219</date></document-id></priority-claim><priority-claim mxw-id="PPC162032460" ucid="EP-14705162-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>14705162</doc-number><kind>A</kind><date>20140218</date></document-id></priority-claim><priority-claim mxw-id="PPC162032567" ucid="EP-2014053087-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2014053087</doc-number><kind>W</kind><date>20140218</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1988521402" load-source="docdb">A61K   9/28        20060101ALI20140912BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988522052" load-source="docdb">A61K   9/20        20060101ALI20140912BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525558" load-source="docdb">A61K   9/16        20060101AFI20140912BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987765820" load-source="docdb" scheme="CPC">A61K  31/517       20130101 LI20140929BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987767376" load-source="docdb" scheme="CPC">A61K   9/2866      20130101 LA20130719BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987773029" load-source="docdb" scheme="CPC">A61K   9/1652      20130101 FI20141001BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987799062" load-source="docdb" scheme="CPC">A61K   9/2054      20130101 LI20141001BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165553844" lang="DE" load-source="patent-office">PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT N-[3-CHLOR-4-(3-FLUORBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]CHINAZOLIN-4-AMIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ, SOLVAT ODER SOLVATISIERTES SALZ DARAUS</invention-title><invention-title mxw-id="PT165553845" lang="EN" load-source="patent-office">PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-(3-FLUOROBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]QUINAZOLIN-4-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR SOLVATED SALT THEREOF</invention-title><invention-title mxw-id="PT165553846" lang="FR" load-source="patent-office">COMPOSITION PHARMACEUTIQUE COMPRENANT DU N-[3-CHLORO-4-(3-FLUOROBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]QUINAZOLIN-4-AMINE OU UN SEL, UN SOLVATE OU UN SEL SOLVATÉ PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103333605" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HEXAL AG</last-name><address><country>DE</country></address></addressbook></applicant><applicant mxw-id="PPAR1103338212" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HEXAL AG</last-name></addressbook></applicant><applicant mxw-id="PPAR1101643480" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Hexal AG</last-name><iid>100139076</iid><address><street>Industriestrasse 25</street><city>83607 Holzkirchen</city><country>DE</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103316426" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ROTHER PATRICK</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR1103320859" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>Rother, Patrick</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649493" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Rother, Patrick</last-name><address><street>Binnenkamp 18</street><city>23858 Reinfeld</city><country>DE</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101646353" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Global IP Europe Patentanwaltskanzlei</last-name><iid>101435897</iid><address><street>Pfarrstraße 14</street><city>80538 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2014053087-W"><document-id><country>EP</country><doc-number>2014053087</doc-number><kind>W</kind><date>20140218</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014128107-A1"><document-id><country>WO</country><doc-number>2014128107</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660741829" load-source="docdb">AL</country><country mxw-id="DS660765729" load-source="docdb">AT</country><country mxw-id="DS660741839" load-source="docdb">BE</country><country mxw-id="DS660652033" load-source="docdb">BG</country><country mxw-id="DS660646358" load-source="docdb">CH</country><country mxw-id="DS660729613" load-source="docdb">CY</country><country mxw-id="DS660765730" load-source="docdb">CZ</country><country mxw-id="DS660741840" load-source="docdb">DE</country><country mxw-id="DS660729614" load-source="docdb">DK</country><country mxw-id="DS660729627" load-source="docdb">EE</country><country mxw-id="DS660649005" load-source="docdb">ES</country><country mxw-id="DS660652034" load-source="docdb">FI</country><country mxw-id="DS660652039" load-source="docdb">FR</country><country mxw-id="DS660741841" load-source="docdb">GB</country><country mxw-id="DS660729628" load-source="docdb">GR</country><country mxw-id="DS660741842" load-source="docdb">HR</country><country mxw-id="DS660765735" load-source="docdb">HU</country><country mxw-id="DS660646367" load-source="docdb">IE</country><country mxw-id="DS660741851" load-source="docdb">IS</country><country mxw-id="DS660652040" load-source="docdb">IT</country><country mxw-id="DS660729629" load-source="docdb">LI</country><country mxw-id="DS660796677" load-source="docdb">LT</country><country mxw-id="DS660765736" load-source="docdb">LU</country><country mxw-id="DS660796678" load-source="docdb">LV</country><country mxw-id="DS660796679" load-source="docdb">MC</country><country mxw-id="DS660731141" load-source="docdb">MK</country><country mxw-id="DS660731142" load-source="docdb">MT</country><country mxw-id="DS660649006" load-source="docdb">NL</country><country mxw-id="DS660765737" load-source="docdb">NO</country><country mxw-id="DS660731147" load-source="docdb">PL</country><country mxw-id="DS660729630" load-source="docdb">PT</country><country mxw-id="DS660649011" load-source="docdb">RO</country><country mxw-id="DS660729635" load-source="docdb">RS</country><country mxw-id="DS660649012" load-source="docdb">SE</country><country mxw-id="DS660729636" load-source="docdb">SI</country><country mxw-id="DS660731148" load-source="docdb">SK</country><country mxw-id="DS660731149" load-source="docdb">SM</country><country mxw-id="DS660646368" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139078776" ref-ucid="WO-2014128107-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof, and a process for preparing the pharmaceutical composition.</p></abstract><abstract mxw-id="PA139545331" ref-ucid="WO-2014128107-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof, and a process for preparing the pharmaceutical composition.</p></abstract><abstract mxw-id="PA139078777" ref-ucid="WO-2014128107-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne une composition pharmaceutique comprenant du [3-chloro-4-(3- fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine ou un sel, un solvate ou un sel solvaté pharmaceutiquement acceptable de celui-ci, ainsi qu'un procédé pour préparer la composition pharmaceutique.</p></abstract><abstract mxw-id="PA139545332" ref-ucid="WO-2014128107-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne une composition pharmaceutique comprenant du [3-chloro-4-(3- fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine ou un sel, un solvate ou un sel solvaté pharmaceutiquement acceptable de celui-ci, ainsi qu'un procédé pour préparer la composition pharmaceutique.</p></abstract><description mxw-id="PDES78477695" ref-ucid="WO-2014128107-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> Pharmaceutical composition comprising N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2- (methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof </p><p id="p0002" num="0002">FIELD OF THE INVENTION </p><p id="p0003" num="0003">The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-(3- fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4- amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof, and a process for preparing the pharmaceutical composition. </p><p id="p0004" num="0004">BACKGROUND OF THE INVENTION </p><p id="p0005" num="0005">N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2- furyl]quinazolin-4-amine is hereinafter referred to as lapatinib in accordance with the international non-proprietary name (INN) given by the World Health Organization (WHO). Lapatinib ditosylate monohydrate was shown to act as an inhibitor of the intracellular tyrosine kinase domains of certain epidermal growth factor receptors, such as ErbB-1 and ErbB-2, and is currently used in the treatment of patients with breast cancer, whose tumours overexpress ErbB-2. </p><p id="p0006" num="0006">WO 2006/1 13649 discloses oral pharmaceutical compositions comprising an active ingredient, which is for example lapatinib or a salt or solvate thereof, together with a binder, and optionally a disintegrant and a lubricant. </p><p id="p0007" num="0007">WO 2010/023187 discloses pharmaceutical compositions comprising lapatinib or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is present in an amount of more than 60% by weight based on the total weight of the composition. </p><p id="p0008" num="0008">WO 2010/023188 discloses pharmaceutical compositions comprising lapatinib or a pharmaceutically acceptable salt thereof wherein a unit dose of the composition contains 1200 to 1300 mg of the active pharmaceutical ingredient calculated as the free base. 
<!-- EPO <DP n="3"/>-->
 SUMMARY OF THE INVENTION </p><p id="p0009" num="0009">It has now been found that a pharmaceutical composition comprising lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, at least one binder, at least one disintegrant, at least one lubricant, and at least one filler, wherein the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, is associated with advantages compared to prior art compositions. In particular, the pharmaceutical composition according to the present invention can be prepared in a cost and time efficient way, especially large scale </p><p id="p0010" num="0010">manufacturing can be done at high speed without producing a significant number of defective products with regard to tablet weight and tablet appearance, whereby the pharmaceutical composition shows a desired dissolution behaviour. </p><p id="p0011" num="0011">DETAILED DESCRIPTION OF THE INVENTION </p><p id="p0012" num="0012">Lapatinib and the pharmaceutically acceptable salts, solvates and solvated salts thereof can be prepared as described in WO 99/35146 and WO 02/02552. </p><p id="p0013" num="0013">Lapatinib or the pharmaceutically acceptable salt or solvate or solvated salt thereof is preferably present in the pharmaceutical composition according to the present invention in an amount of from 30 to 60% by weight, relative to the weight of the pharmaceutical </p><p id="p0014" num="0014">composition, more preferably in an amount of from 40 to 60% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0015" num="0015">Preferably, the pharmaceutical composition according to the present invention contains 250 mg, 500 mg, 750 mg, 1000 mg or 1250 mg of lapatinib or the pharmaceutically acceptable salt or solvate or solvated salt thereof (calculated as the free base). Most preferably, the pharmaceutical composition according to the present invention contains 250 mg of lapatinib or the pharmaceutically acceptable salt or solvate or solvated salt thereof (calculated as the free base). </p><p id="p0016" num="0016">Pharmaceutically acceptable salts of lapatinib include, for example, the hydrochloride, hydrobromide, sulfate, nitrate, acetate, tartrate, citrate, fumarate, lactate, malate, maleate, mesylate, pamoate, oxalate, gluconate, salicylate, benzoate, succinate, and tosylate salts. 
<!-- EPO <DP n="4"/>-->
 Preferred pharmaceutically acceptable salts of lapatinib include the monomesylate, the dimesylate, the monotosylate and the ditosylate salt, in particular the ditosylate anhydrate salt. The pharmaceutically acceptable solvates of lapatinib include the hydrates of lapatinib. The monohydrate of lapatinib is particularly preferred. Pharmaceutically acceptable solvated salts of lapatinib include lapatinib mesylate monohydrate, lapatinib dimesylate monohydrate, lapatinib tosylate monohydrate, and lapatinib ditosylate monohydrate. Lapatinib ditosylate monohydrate is most preferred. </p><p id="p0017" num="0017">In a preferred embodiment, the pharmaceutical composition of the present invention comprises a binder selected from the group consisting of gelatine, polyvinyl pyrrolidone (PVP), polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose (HPC), </p><p id="p0018" num="0018">hydroxypropylmethylcellulose (HPMC) and combinations thereof. </p><p id="p0019" num="0019">The binder is preferably present in the pharmaceutical composition of the present invention in an amount of from 1 to 20% by weight, relative to the weight of the pharmaceutical composition, preferably in an amount of from 5 to 10% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0020" num="0020">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof. </p><p id="p0021" num="0021">Crospovidone is a cross-linked polyvinylpyrrolidone. It is formed by so-called popcorn- polymerization of vinylpyrrolidone. Examples of crospovidone include Kollidon CL, Kollidon CL-M, PolyKoVidone, Polyplasdone XL and Polyplasdone XL-10. A preferred example is Polyplasdone XL. </p><p id="p0022" num="0022">The disintegrant is preferably present in the pharmaceutical composition of the present invention in an amount of from 0.5 to 8% by weight, relative to the weight of the </p><p id="p0023" num="0023">pharmaceutical composition, preferably in an amount of from 4 to 6% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0024" num="0024">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises a lubricant selected from the group consisting of magnesium stearate, calcium 
<!-- EPO <DP n="5"/>-->
 stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof. </p><p id="p0025" num="0025">The lubricant is preferably present in the pharmaceutical composition of the present invention in an amount of from of 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, preferably in an amount of from 0.5 to 2% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0026" num="0026">The microcrystalline cellulose is present in the pharmaceutical composition of the present invention in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. Preferably, the microcrystalline cellulose has a median particle size of 50 to 100 μηι. The particle size distribution is measured by laser diffraction on a Mastersizer 2000 with dry powder dispersion unit Scirocco 2000 (Measurement conditions: Sample weight is 1000 mg; the feed rate with a micro feed tray is 80%; the dispersion pressure is 2 bar; the diffraction method is Frauenhofer with analysis model "general purpose" and refraction index of particles is 0.000; measurement time is 12 s; background time is 12 s). </p><p id="p0027" num="0027">In a preferred embodiment, the pharmaceutical composition of the present invention comprises mannitol, more preferably in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0028" num="0028">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises calcium hydrogen phosphate. The calcium hydrogen phosphate may be present in the form of calcium hydrogen phosphate anhydrate or calcium hydrogen phosphate dihydrate. In a particularly preferred embodiment, the pharmaceutical composition of the present invention comprises calcium hydrogen phosphate in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0029" num="0029">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises lactose. In a particularly preferred embodiment, the pharmaceutical composition of the present invention comprises lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. The lactose can be present as alpha-lactose 
<!-- EPO <DP n="6"/>-->
 anhydrate, alpha-lactose monohydrate, beta-lactose, amorphous lactose, crystalline lactose or mixtures thereof. Alpha-lactose monohydrate is most preferred. </p><p id="p0030" num="0030">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises starch. The starch is, for example, maize starch, wheat starch, rice starch and/or potato starch, and can be present as natural starch and/or pre-treated starch, such as pregelatinized starch or thermally treated starch. In a particularly preferred embodiment, the pharmaceutical composition of the present invention comprises the starch in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0031" num="0031">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0032" num="0032">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0033" num="0033">at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0034" num="0034">at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0035" num="0035">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0036" num="0036">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0037" num="0037">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0038" num="0038">at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0039" num="0039">at least one lubricant selected from the group consisting of magnesium stearate, calcium 
<!-- EPO <DP n="7"/>-->
 stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0040" num="0040">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0041" num="0041">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0042" num="0042">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0043" num="0043">at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0044" num="0044">at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0045" num="0045">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0046" num="0046">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0047" num="0047">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0048" num="0048">at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; 
<!-- EPO <DP n="8"/>-->
 at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0049" num="0049">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0050" num="0050">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0051" num="0051">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0052" num="0052">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0053" num="0053">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0054" num="0054">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0055" num="0055">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0056" num="0056">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0057" num="0057">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0058" num="0058">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; 
<!-- EPO <DP n="9"/>-->
 at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0059" num="0059">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0060" num="0060">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0061" num="0061">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0062" num="0062">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0063" num="0063">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0064" num="0064">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0065" num="0065">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0066" num="0066">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0067" num="0067">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; 
<!-- EPO <DP n="10"/>-->
 at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0068" num="0068">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0069" num="0069">lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a binder selected from the group consisting of polyvinyl pyrrolidone, </p><p id="p0070" num="0070">hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0071" num="0071">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </p><p id="p0072" num="0072">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0073" num="0073">a filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0074" num="0074">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0075" num="0075">lapatinib ditosylate monohydrate, </p><p id="p0076" num="0076">a binder selected from the group consisting of polyvinyl pyrrolidone, </p><p id="p0077" num="0077">hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0078" num="0078">a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </p><p id="p0079" num="0079">a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0080" num="0080">a filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of lactose. 
<!-- EPO <DP n="11"/>-->
 ln a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0081" num="0081"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0082" num="0082"> 1 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0083" num="0083"> 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0084" num="0084"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0085" num="0085">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0086" num="0086">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0087" num="0087"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0088" num="0088"> 1 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0089" num="0089"> 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0090" num="0090"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium 
<!-- EPO <DP n="12"/>-->
 arachinate, calcium arachinate, and combinations thereof; </p><p id="p0091" num="0091">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0092" num="0092">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0093" num="0093"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0094" num="0094"> 1 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one binder selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0095" num="0095"> 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of at least one disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0096" num="0096"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof; </p><p id="p0097" num="0097">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0098" num="0098">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0099" num="0099"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0100" num="0100">1 to 20% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; 
<!-- EPO <DP n="13"/>-->
 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0101" num="0101"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0102" num="0102">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0103" num="0103">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0104" num="0104"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0105" num="0105">1 to 20% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0106" num="0106"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0107" num="0107">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </p><p id="p0108" num="0108">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0109" num="0109"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, 
<!-- EPO <DP n="14"/>-->
 1 to 20% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </p><p id="p0110" num="0110"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0111" num="0111">at least one filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </p><p id="p0112" num="0112">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises </p><p id="p0113" num="0113"> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, </p><p id="p0114" num="0114">1 to 20% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0115" num="0115"> 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </p><p id="p0116" num="0116"> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0117" num="0117">a filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of lactose. </p><p id="p0118" num="0118">In a further preferred embodiment, the pharmaceutical composition of the present invention comprises 
<!-- EPO <DP n="15"/>-->
 40 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib ditosylate monohydrate, </p><p id="p0119" num="0119"> 5 to 10% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, hydroxypropylmethylcellulose and combinations thereof; </p><p id="p0120" num="0120"> 4 to 6% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </p><p id="p0121" num="0121"> 0.5 to 2% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </p><p id="p0122" num="0122">a filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of the pharmaceutical composition, of lactose. </p><p id="p0123" num="0123">The pharmaceutical composition of the present invention can further comprise a glidant, for example, colloidal silicon dioxide. </p><p id="p0124" num="0124">The pharmaceutical composition of the present invention can further comprise a colorant, for example, ferric oxide. </p><p id="p0125" num="0125">The pharmaceutical composition according to the present invention is preferably a tablet or coated tablet. More preferably, the pharmaceutical composition according to the present invention is a coated tablet. </p><p id="p0126" num="0126">The coating may comprise for example a cellulose, such as hydroxypropylmethylcellulose, a polyethylene glycol, such as Macrogol 400, a sorbitan fatty acid ester, such as Polysorbate 80, and/or titanium dioxide. Optionally, the coating may comprise a colorant, such as ferric oxide or an aluminum lake (e.g. sunset yellow aluminum lake E1 10). Commercially available coating compositions, such as Opadry coating compositions (e.g. Opadry® YS-1 -13065-A) can be used. 
<!-- EPO <DP n="16"/>-->
 The pharmaceutical composition according to the present invention can be prepared by a process comprising a wet granulation step. Examples of wet granulation include wet granulation in a swaying granulator, high shear wet granulation, and fluidized bed granulation. High shear wet granulation is preferred. </p><p id="p0127" num="0127">The pharmaceutical composition according to the present invention can be produced by a process comprising: </p><p id="p0128" num="0128"> (a) granulating a mixture comprising lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, a filler, and optionally a disintegrant, using an aqueous solution of the binder as granulation liquid; </p><p id="p0129" num="0129"> (b) drying the granules obtained in step (a); </p><p id="p0130" num="0130"> (c) mixing the dried granules with the lubricant, and optionally the disintegrant; </p><p id="p0131" num="0131">provided that the disintegrant is added in step (a) and/or (c). </p><p id="p0132" num="0132">If the pharmaceutical composition according to the present invention is a tablet or coated tablet, the process may comprise an additional step of compressing the mixture obtained in step (c) into tablets. </p><p id="p0133" num="0133">Preferably, the granules are dried to a water content of not more than 3% by weight, more preferably of from 0.5 to 3% by weight, in above step (b). The water content can be determined as described in Ph. Eur. 7.0 by measuring the loss on drying (determined on 1 g of the granules dried in an oven at 105°C for 3 h). </p><p id="p0134" num="0134">A preferred process for preparing the pharmaceutical composition according to the present invention includes the following steps: </p><p id="p0135" num="0135"> A dry blend of lapatinib or the pharmaceutically acceptable salt or solvate or solvated salt thereof, the filler and a part of the disintegrant (optionally all sieved before through a Frewitt 1 .0 mm sieve) is filled into a wet granulator, such as a Glatt VG 25 granulator. The binder is dissolved in a suitable amount of purified water and then added to the dry blend under continuous stirring. Wet granulation is preferably performed at a temperature of from 20 to 30°C. The wet granules are then dried in a fluidized bed dryer, such as a Glatt GPCG 3/5 dryer, preferably at a temperature of from 30 to 40°C. The granules are sieved, e.g. through a Frewitt 1 .0 mm sieve, and blended for 5 to 10 minutes in a turbula mixer at 25 rpm with the remaining part of the disintegrant. The lubricant, preferably after having been sieved through 
<!-- EPO <DP n="17"/>-->
 a 0.5 mm sieve, is added to the resulting blend, and the final blend is mixed in a turbula mixer at 25 rpm for 1 to 5 minutes. The final blend is compressed into tablets, for example in a Kilian RTS 24 tablet press. Optionally, the tablets are coated, for example in a Glatt Mini coater (0.8 I drum) using a suitable film-coating preparation, for example Opadry® YS-1 - 13065-A. </p><p id="p0136" num="0136">Another preferred process for preparing the pharmaceutical composition according to the present invention includes the following steps: </p><p id="p0137" num="0137"> A dry blend of lapatinib or the pharmaceutically acceptable salt or solvate or solvated salt thereof, the filler and a part of the disintegrant (optionally all sieved before through a Frewitt 1 .0 mm sieve) is filled into a fluid-bed-granulator, such as a Glatt GPCG 3/5 granulator. The binder is dissolved in a suitable amount of purified water. Fluid-bed-granulation is started and the binder solution sprayed on top of the dry blend (e.g. through a 1 .0 mm spraying nozzle) preferably at a temperature of from 20 to 30°C. The wet granules are then dried in the fluid- bed-granulator preferably at a temperature of from 30 to 40°C. The granules are sieved, e.g. through a Frewitt 1 .0 mm sieve, and blended for 5 to 10 minutes in a turbula mixer at 25 rpm with the remaining part of the disintegrant (optionally sieved before through a Frewitt 1 .0 mm sieve). The lubricant, preferably after having been sieved through a 0.5 mm sieve, is added to the resulting blend and the final blend is mixed in a turbula mixer at 25 rpm for 1 to 5 minutes. The final blend is compressed into tablets, for example in a Kilian RTS 24 tablet press. Optionally, the tablets are coated, for example in a Glatt Mini coater (0.8 I drum) using a suitable film-coating preparation, for example Opadry® YS-1 -13065-A. </p><p id="p0138" num="0138">The pharmaceutical composition according to the present invention optionally comprises a coating. The coating can be prepared by </p><p id="p0139" num="0139"> (i) suspending the components of the coating in water, an organic solvent (for example ethanol) or a mixture of water and an organic solvent (for example a water/ethanol mixture), </p><p id="p0140" num="0140"> (ii) coating the pharmaceutical composition with the thus obtained suspension using a suitable coating device, for example a fluid-bed-coater or a pan coater, and </p><p id="p0141" num="0141"> (iii) drying the coated pharmaceutical composition. </p><p id="p0142" num="0142">The pharmaceutical composition of the present invention may be useful in the treatment of cancer including breast cancer, ovarian cancer, brain cancer, head cancer, neck cancer, 
<!-- EPO <DP n="18"/>-->
 gastric cancer, colorectal cancer, prostate cancer, bladder cancer or prostate cancer. The pharmaceutical composition of the present invention may further be useful in the treatment of psoriasis. </p><p id="p0143" num="0143">The pharmaceutical composition of the present invention can comprise a further active ingredient selected from anti-neoplastic agents, such as paclitaxel, docetaxel, gemcitabine, irinotecan, topotecan, cisplatin, carboplatin, oxaliplatin, capecitabine, anastrozole, letrozole, pazopanib, imatinib, erlotinib, dasatinib, sorafenib, sunitinib and gefitinib. </p><p id="p0144" num="0144">EXAMPLES </p><p id="p0145" num="0145">Example 1 </p><p id="p0146" num="0146"><img id="imgf000018_0001" he="57" wi="124" file="imgf000018_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0147" num="0147">Total weight of film-coated tablet: 675 mg </p><p id="p0148" num="0148">Each of the lapatinib ditosylate monohydrate, microcrystalline cellulose and sodium starch glycolate are sieved through a Frewitt 1 .0 mm sieve. A dry blend of the sieved lapatinib ditosylate monohydrate, the sieved microcrystalline cellulose and half of the sieved sodium starch glycolate is filled into a wet granulator (Glatt, VG 25 granulator). The polyvinyl pyrrolidone is dissolved in purified water (5 parts per weight of water per 1 part per weight of polyvinyl pyrrolidone) and then added to the dry blend under continuous stirring. Wet granulation is performed at 20°C. The wet granules are then dried in a fluidized bed dryer (Glatt, GPCG 3/5) at 35°C. The granules are sieved through a Frewitt 1 .0 mm sieve and blended for 10 minutes in a turbula mixer at 25 rpm with the second half of the sieved sodium starch glycolate. Magnesium stearate is added to the resulting blend after having been 
<!-- EPO <DP n="19"/>-->
 sieved through a 0.5 mm hand sieve and the blend thus obtained is mixed in a turbula mixer at 25 rpm for 3 minutes. The final blend is compressed into tablets using a Kilian RTS 24 tablet press. The tablets are coated in a Glatt Mini coater (0.8 I drum) using a the commercially available Opadry® YS-1 -13065-A film coating. </p><p id="p0149" num="0149">Example 2 </p><p id="p0150" num="0150"><img id="imgf000019_0001" he="57" wi="124" file="imgf000019_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0151" num="0151">Total weight of film-coated tablet: 675 mg </p><p id="p0152" num="0152">The coated tablets are prepared as described in Example 1 with the exception that calcium behenate is used in place of magnesium stearate. </p><p id="p0153" num="0153">Example 3 </p><p id="p0154" num="0154"><img id="imgf000019_0002" he="57" wi="124" file="imgf000019_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0155" num="0155">Total weight of film-coated tablet: 675 mg 
<!-- EPO <DP n="20"/>-->
 The coated tablets are prepared as described in Example 1 with the exception that calcium stearate is used in place of magnesium stearate. </p><p id="p0156" num="0156">Example 4 </p><p id="p0157" num="0157"><img id="imgf000020_0001" he="57" wi="124" file="imgf000020_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0158" num="0158">Total weight of film-coated tablet: 675 mg </p><p id="p0159" num="0159">The coated tablets are prepared as described in Example 1 with the exception that HPMC is used in place of polyvinyl pyrrolidone. </p><p id="p0160" num="0160">Example 5 </p><p id="p0161" num="0161"><img id="imgf000020_0002" he="57" wi="124" file="imgf000020_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0162" num="0162">Total weight of film-coated tablet: 675 mg </p><p id="p0163" num="0163">The coated tablets are prepared as described in Example 1 with the exception that croscarmellose sodium is used in place of sodium starch glycolate. 
<!-- EPO <DP n="21"/>-->
 Example 6 </p><p id="p0164" num="0164"><img id="imgf000021_0001" he="57" wi="124" file="imgf000021_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0165" num="0165">Total weight of film-coated tablet: 675 mg </p><p id="p0166" num="0166">The coated tablets are prepared as described in Example 1 with the exception that HPMC is used in place of polyvinyl pyrrolidone and croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0167" num="0167">Example 7 </p><p id="p0168" num="0168"><img id="imgf000021_0002" he="63" wi="124" file="imgf000021_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0169" num="0169">Total weight of film-coated tablet: 675 mg </p><p id="p0170" num="0170">Each of the lapatinib ditosylate monohydrate, microcrystalline cellulose, alpha-lactose monohydrate and sodium starch glycolate are sieved through a Frewitt 1 .0 mm sieve. A dry 
<!-- EPO <DP n="22"/>-->
 blend of the sieved lapatinib ditosylate monohydrate, the sieved microcrystalline cellulose, the sieved alpha-lactose monohydrate and half of the sieved sodium starch glycolate is filled into a wet granulator (Glatt, VG 25 granulator). The polyvinyl pyrrolidone is dissolved in purified water (5 parts per weight of water per 1 part per weight of polyvinyl pyrrolidone) and then added to the dry blend under continuous stirring. Wet granulation is performed at 20°C. The wet granules are then dried in a fluidized bed dryer (Glatt, GPCG 3/5) at 35°C. The granules are sieved through a Frewitt 1 .0 mm sieve and blended for 10 minutes in a turbula mixer at 25 rpm with the second half of the sieved sodium starch glycolate. Magnesium stearate is added to the resulting blend after having been sieved through a 0.5 mm hand sieve and the blend thus obtained is mixed in a turbula mixer at 25 rpm for 3 minutes. The final blend is compressed into tablets using a Kilian RTS 24 tablet press. The tablets are coated in a Glatt Mini coater (0.8 I drum) using a commercially available Opadry® YS-1 - 13065-A film coating. </p><p id="p0171" num="0171">Example 8 </p><p id="p0172" num="0172"><img id="imgf000022_0001" he="63" wi="124" file="imgf000022_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0173" num="0173">Total weight of film-coated tablet: 675 mg </p><p id="p0174" num="0174">The coated tablets are prepared as described in Example 7 with the exception that HPMC is used in place of polyvinyl pyrrolidone. </p><p id="p0175" num="0175">Example 9 </p><p id="p0176" num="0176">Component Content in film-coated tablet 
<!-- EPO <DP n="23"/>-->
 [% by weight] </p><p id="p0177" num="0177"> Lapatinib ditosylate monohydrate 60.0 </p><p id="p0178" num="0178"> Polyvinyl pyrrolidone 7.5 </p><p id="p0179" num="0179"> Croscarmellose sodium 5.5 </p><p id="p0180" num="0180"> Microcrystalline cellulose 12.6 </p><p id="p0181" num="0181"> Alpha-lactose monohydrate 10.0 </p><p id="p0182" num="0182"> Magnesium stearate 1 .4 </p><p id="p0183" num="0183"> Film coating 3.0 </p><p id="p0184" num="0184">Total weight of film-coated tablet: 675 mg </p><p id="p0185" num="0185">The coated tablets are prepared as described in Example 7 with the exception that croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0186" num="0186">Example 10 </p><p id="p0187" num="0187"><img id="imgf000023_0001" he="63" wi="124" file="imgf000023_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0188" num="0188">Total weight of film-coated tablet: 675 mg </p><p id="p0189" num="0189">The coated tablets are prepared as described in Example 7 with the exception that HPMC is used in place of polyvinyl pyrrolidone and croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0190" num="0190">Example 1 1 
<!-- EPO <DP n="24"/>-->
 Component Content in film-coated tablet </p><p id="p0191" num="0191"> [% by weight] </p><p id="p0192" num="0192"> Lapatinib ditosylate monohydrate 60.0 </p><p id="p0193" num="0193"> HPMC 7.5 </p><p id="p0194" num="0194"> Croscarmellose sodium 5.5 </p><p id="p0195" num="0195"> Microcrystalline cellulose 12.6 </p><p id="p0196" num="0196"> Alpha-lactose monohydrate 10.0 </p><p id="p0197" num="0197"> Calcium behenate 1 .4 </p><p id="p0198" num="0198"> Film coating 3.0 </p><p id="p0199" num="0199">Total weight of film-coated tablet: 675 mg </p><p id="p0200" num="0200">The coated tablets are prepared as described in Example 7 with the exception that HPMC is used in place of polyvinyl pyrrolidone, croscarmellose sodium is used in place of sodium starch glycolate, and calcium behenate is used in place of magnesium stearate. </p><p id="p0201" num="0201">Example 12 </p><p id="p0202" num="0202"><img id="imgf000024_0001" he="63" wi="124" file="imgf000024_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0203" num="0203">Total weight of film-coated tablet: 779 mg </p><p id="p0204" num="0204">Each of the lapatinib ditosylate monohydrate, microcrystalline cellulose, alpha-lactose monohydrate and sodium starch glycolate are sieved through a Frewitt 1 .0 mm sieve. A dry blend of the sieved lapatinib ditosylate monohydrate, the sieved microcrystalline cellulose, the sieved alpha-lactose monohydrate and half of the sieved sodium starch glycolate is filled 
<!-- EPO <DP n="25"/>-->
 into a fluid-bed-granulator (Glatt, GPCG 3/5 granulator). The polyvinyl pyrrolidone is dissolved in purified water (5 parts per weight of water per 1 part per weight of polyvinyl pyrrolidone). Fluid-bed-granulation is started and the polyvinyl pyrrolidone solution is sprayed on top of the dry blend through a 1 .0 mm spraying nozzle at 25°C. The wet granules are then further dried in the fluid bed granulator at 35°C. The granules are sieved through a Frewitt 1 .0 mm sieve and blended for 10 minutes in a turbula mixer at 25 rpm with the second half of the sieved sodium starch glycolate. Magnesium stearate is added to the resulting blend after having been sieved through a 0.5 mm hand sieve and the blend thus obtained is mixed in a turbula mixer at 25 rpm for 3 minutes. The final blend is compressed into tablets using a Kilian RTS 24 tablet press. The tablets are coated in a Glatt Mini coater (0.8 I drum) using a commercially available Opadry® YS-1 -13065-A film coating. </p><p id="p0205" num="0205">Example 13 </p><p id="p0206" num="0206"><img id="imgf000025_0001" he="63" wi="124" file="imgf000025_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0207" num="0207">Total weight of film-coated tablet: 779 mg </p><p id="p0208" num="0208">The coated tablets are prepared as described in Example 12 with the exception that calcium stearate is used in place of magnesium stearate. </p><p id="p0209" num="0209">Example 14 </p><p id="p0210" num="0210">Component Content in film-coated tablet </p><p id="p0211" num="0211"> [% by weight] </p><p id="p0212" num="0212"> Lapatinib ditosylate monohydrate 52.0 
<!-- EPO <DP n="26"/>-->
 HPMC 7.0 </p><p id="p0213" num="0213"> Sodium starch glycolate 5.0 </p><p id="p0214" num="0214"> Microcrystalline cellulose 18.8 </p><p id="p0215" num="0215"> Alpha-lactose monohydrate 13.0 </p><p id="p0216" num="0216"> Magnesium stearate 1 .2 </p><p id="p0217" num="0217"> Film coating 3.0 </p><p id="p0218" num="0218">Total weight of film-coated tablet: 779 mg </p><p id="p0219" num="0219">The coated tablets are prepared as described in Example 12 with the exception that HPMC is used in place of polyvinyl pyrrolidone. </p><p id="p0220" num="0220">Example 15 </p><p id="p0221" num="0221"><img id="imgf000026_0001" he="63" wi="124" file="imgf000026_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0222" num="0222">Total weight of film-coated tablet: 779 mg </p><p id="p0223" num="0223">The coated tablets are prepared as described in Example 12 with the exception that croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0224" num="0224">Example 16 </p><p id="p0225" num="0225">Component Content in film-coated tablet </p><p id="p0226" num="0226"> [% by weight] </p><p id="p0227" num="0227"> Lapatinib ditosylate monohydrate 52.0 
<!-- EPO <DP n="27"/>-->
 HPMC 7.0 </p><p id="p0228" num="0228"> Croscarmellose sodium 5.0 </p><p id="p0229" num="0229"> Microcrystalline cellulose 18.8 </p><p id="p0230" num="0230"> Alpha-lactose monohydrate 13.0 </p><p id="p0231" num="0231"> Magnesium stearate 1 .2 </p><p id="p0232" num="0232"> Film coating 3.0 </p><p id="p0233" num="0233">Total weight of film-coated tablet: 779 mg </p><p id="p0234" num="0234">The coated tablets are prepared as described in Example 12 with the exception that HPMC is used in place of polyvinyl pyrrolidone and croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0235" num="0235">Example 17 </p><p id="p0236" num="0236"><img id="imgf000027_0001" he="63" wi="124" file="imgf000027_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0237" num="0237">Total weight of film-coated tablet: 779 mg </p><p id="p0238" num="0238">The coated tablets are prepared as described in Example 12 with the exception that HPMC is used in place of polyvinyl pyrrolidone, croscarmellose sodium is used in place of sodium starch glycolate, and calcium stearate is used in place of magnesium stearate. </p><p id="p0239" num="0239">Example 18 </p><p id="p0240" num="0240">Component Content in film-coated tablet 
<!-- EPO <DP n="28"/>-->
 [% by weight] </p><p id="p0241" num="0241"> Lapatinib ditosylate monohydrate 44.0 </p><p id="p0242" num="0242"> Polyvinyl pyrrolidone 6.5 </p><p id="p0243" num="0243"> Sodium starch glycolate 4.5 </p><p id="p0244" num="0244"> Microcrystalline cellulose 25.0 </p><p id="p0245" num="0245"> Alpha-lactose monohydrate 16.0 </p><p id="p0246" num="0246"> Magnesium stearate 1 .0 </p><p id="p0247" num="0247"> Film coating 3.0 </p><p id="p0248" num="0248">Total weight of film-coated tablet: 920 mg </p><p id="p0249" num="0249">The coated tablets are prepared as described in Example 7 with the exception that the components are used in the amounts as indicated in the above table. </p><p id="p0250" num="0250">Example 19 </p><p id="p0251" num="0251"><img id="imgf000028_0001" he="63" wi="124" file="imgf000028_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0252" num="0252">Total weight of film-coated tablet: 920 mg </p><p id="p0253" num="0253">The coated tablets are prepared as described in Example 18 with the exception that calcium arachinate is used in place of magnesium stearate. </p><p id="p0254" num="0254">Example 20 </p><p id="p0255" num="0255">Component Content in film-coated tablet 
<!-- EPO <DP n="29"/>-->
 [% by weight] </p><p id="p0256" num="0256"> Lapatinib ditosylate monohydrate 44.0 </p><p id="p0257" num="0257"> HPMC 6.5 </p><p id="p0258" num="0258"> Sodium starch glycolate 4.5 </p><p id="p0259" num="0259"> Microcrystalline cellulose 25.0 </p><p id="p0260" num="0260"> Alpha-lactose monohydrate 16.0 </p><p id="p0261" num="0261"> Magnesium stearate 1 .0 </p><p id="p0262" num="0262"> Film coating 3.0 </p><p id="p0263" num="0263">Total weight of film-coated tablet: 920 mg </p><p id="p0264" num="0264">The coated tablets are prepared as described in Example 18 with the exception that HPMC is used in place of polyvinyl pyrrolidone. </p><p id="p0265" num="0265">Example 21 </p><p id="p0266" num="0266"><img id="imgf000029_0001" he="63" wi="124" file="imgf000029_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0267" num="0267">Total weight of film-coated tablet: 920 mg </p><p id="p0268" num="0268">The coated tablets are prepared as described in Example 18 with the exception that croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0269" num="0269">Example 22 </p><p id="p0270" num="0270">Component Content in film-coated tablet 
<!-- EPO <DP n="30"/>-->
 [% by weight] </p><p id="p0271" num="0271"> Lapatinib ditosylate monohydrate 44.0 </p><p id="p0272" num="0272"> HPMC 6.5 </p><p id="p0273" num="0273"> Croscarmellose sodium 4.5 </p><p id="p0274" num="0274"> Microcrystalline cellulose 25.0 </p><p id="p0275" num="0275"> Alpha-lactose monohydrate 16.0 </p><p id="p0276" num="0276"> Magnesium stearate 1 .0 </p><p id="p0277" num="0277"> Film coating 3.0 </p><p id="p0278" num="0278">Total weight of film-coated tablet: 920 mg </p><p id="p0279" num="0279">The coated tablets are prepared as described in Example 18 with the exception that HPMC is used in place of polyvinyl pyrrolidone and croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0280" num="0280">Example 23 </p><p id="p0281" num="0281"><img id="imgf000030_0001" he="63" wi="124" file="imgf000030_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0282" num="0282">Total weight of film-coated tablet: 920 mg </p><p id="p0283" num="0283">The coated tablets are prepared as described in Example 18 with the exception that HPMC is used in place of polyvinyl pyrrolidone, croscarmellose sodium is used in place of sodium starch glycolate, and calcium arachinate is used in place of magnesium stearate. </p><p id="p0284" num="0284">Example 24 
<!-- EPO <DP n="31"/>-->
 Component Content in film-coated tablet </p><p id="p0285" num="0285"> [% by weight] </p><p id="p0286" num="0286"> Lapatinib ditosylate monohydrate 40.5 </p><p id="p0287" num="0287"> Polyvinyl pyrrolidone 6.2 </p><p id="p0288" num="0288"> Sodium starch glycolate 4.3 </p><p id="p0289" num="0289"> Microcrystalline cellulose 28.0 </p><p id="p0290" num="0290"> Alpha-lactose monohydrate 17.0 </p><p id="p0291" num="0291"> Magnesium stearate 1 .0 </p><p id="p0292" num="0292"> Film coating 3.0 </p><p id="p0293" num="0293">Total weight of film-coated tablet: 1000 mg </p><p id="p0294" num="0294">The coated tablets are prepared as described in Example 12 with the exception that the components are used in the amounts as indicated in the above table. </p><p id="p0295" num="0295">Example 25 </p><p id="p0296" num="0296"><img id="imgf000031_0001" he="63" wi="124" file="imgf000031_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0297" num="0297">Total weight of film-coated tablet: 1000 mg </p><p id="p0298" num="0298">The coated tablets are prepared as described in Example 24 with the exception that calcium stearate is used in place of magnesium stearate. </p><p id="p0299" num="0299">Example 26 
<!-- EPO <DP n="32"/>-->
 Component Content in film-coated tablet </p><p id="p0300" num="0300"> [% by weight] </p><p id="p0301" num="0301"> Lapatinib ditosylate monohydrate 40.5 </p><p id="p0302" num="0302"> HPMC 6.2 </p><p id="p0303" num="0303"> Sodium starch glycolate 4.3 </p><p id="p0304" num="0304"> Microcrystalline cellulose 28.0 </p><p id="p0305" num="0305"> Alpha-lactose monohydrate 17.0 </p><p id="p0306" num="0306"> Magnesium stearate 1 .0 </p><p id="p0307" num="0307"> Film coating 3.0 </p><p id="p0308" num="0308">Total weight of film-coated tablet: 1000 mg </p><p id="p0309" num="0309">The coated tablets are prepared as described in Example 24 with the e&gt; </p><p id="p0310" num="0310">is used in place of polyvinyl pyrrolidone. </p><p id="p0311" num="0311">Example 27 </p><p id="p0312" num="0312">Component Content in film-coated tablet </p><p id="p0313" num="0313"> [% by weight] </p><p id="p0314" num="0314"> Lapatinib ditosylate monohydrate 40.5 </p><p id="p0315" num="0315"> Polyvinyl pyrrolidone 6.2 </p><p id="p0316" num="0316"> Croscarmellose sodium 4.3 </p><p id="p0317" num="0317"> Microcrystalline cellulose 28.0 </p><p id="p0318" num="0318"> Alpha-lactose monohydrate 17.0 </p><p id="p0319" num="0319"> Magnesium stearate 1 .0 </p><p id="p0320" num="0320"> Film coating 3.0 </p><p id="p0321" num="0321">Total weight of film-coated tablet: 1000 mg </p><p id="p0322" num="0322">The coated tablets are prepared as described in Example 24 with the exception that croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0323" num="0323">Example 28 
<!-- EPO <DP n="33"/>-->
 Component Content in film-coated tablet </p><p id="p0324" num="0324"> [% by weight] </p><p id="p0325" num="0325"> Lapatinib ditosylate monohydrate 40.5 </p><p id="p0326" num="0326"> HPMC 6.2 </p><p id="p0327" num="0327"> Croscarmellose sodium 4.3 </p><p id="p0328" num="0328"> Microcrystalline cellulose 28.0 </p><p id="p0329" num="0329"> Alpha-lactose monohydrate 17.0 </p><p id="p0330" num="0330"> Magnesium stearate 1 .0 </p><p id="p0331" num="0331"> Film coating 3.0 </p><p id="p0332" num="0332">Total weight of film-coated tablet: 1000 mg </p><p id="p0333" num="0333">The coated tablets are prepared as described in Example 24 with the exception that HPMC is used in place of polyvinyl pyrrolidone and croscarmellose sodium is used in place of sodium starch glycolate. </p><p id="p0334" num="0334">Example 29 </p><p id="p0335" num="0335"><img id="imgf000033_0001" he="63" wi="124" file="imgf000033_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0336" num="0336">Total weight of film-coated tablet: 1000 mg </p><p id="p0337" num="0337">The coated tablets are prepared as described in Example 24 with the exception that HPMC is used in place of polyvinyl pyrrolidone, croscarmellose sodium is used in place of sodium starch glycolate, and calcium stearate is used in place of magnesium stearate. </p><p id="p0338" num="0338">Example 30 
<!-- EPO <DP n="34"/>-->
 Component Content in film-coated tablet </p><p id="p0339" num="0339"> [% by weight] </p><p id="p0340" num="0340"> Lapatinib ditosylate monohydrate 40.5 </p><p id="p0341" num="0341"> HPMC 6.2 </p><p id="p0342" num="0342"> Croscarmellose sodium 4.3 </p><p id="p0343" num="0343"> Microcrystalline cellulose 28.0 </p><p id="p0344" num="0344"> Alpha-lactose monohydrate 17.0 </p><p id="p0345" num="0345"> Sodium stearyl fumarate 1 .0 </p><p id="p0346" num="0346"> Film coating 3.0 </p><p id="p0347" num="0347">Total weight of film-coated tablet: 1000 mg </p><p id="p0348" num="0348">The coated tablets are prepared as described in Example 24 with the exception that HPMC is used in place of polyvinyl pyrrolidone, croscarmellose sodium is used in place of sodium starch glycolate, and sodium stearyl fumarate is used in place of magnesium stearate. 
</p></description><claims mxw-id="PCLM70077975" ref-ucid="WO-2014128107-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="35"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1 . A pharmaceutical composition comprising an active ingredient, at least one binder, at least one disintegrant, at least one lubricant, and at least one filler, </claim-text><claim-text> wherein the active ingredient is lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof; and the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. A pharmaceutical composition according to claim 1 , wherein the binder is selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. A pharmaceutical composition according to claim 1 or 2, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. A pharmaceutical composition according to any of claims 1 to 3, wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. A pharmaceutical composition according to any of claims 1 to 4, wherein the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A pharmaceutical composition according to claim 5, wherein the filler comprises </claim-text><claim-text> microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, relative to the weight of 
<!-- EPO <DP n="36"/>-->
 the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A pharmaceutical composition according to any of claims 1 to 6, wherein </claim-text><claim-text> the binder is selected from the group consisting of gelatine, polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, </claim-text><claim-text> hydroxypropylmethylcellulose and combinations thereof; </claim-text><claim-text> the disintegrant is selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </claim-text><claim-text> the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, talc, aluminum monostearate, aluminum distearate, aluminum tristearate, zinc stearate, stearic acid, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate, and combinations thereof. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. A pharmaceutical composition according to claim 7, wherein </claim-text><claim-text> the binder is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof; </claim-text><claim-text> the disintegrant is selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone and combinations thereof; </claim-text><claim-text> the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A pharmaceutical composition according to claim 8, wherein </claim-text><claim-text> the binder is selected from the group consisting of polyvinyl pyrrolidone, </claim-text><claim-text> hydroxypropylmethylcellulose and combinations thereof; </claim-text><claim-text> the disintegrant is selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </claim-text><claim-text> the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </claim-text><claim-text> the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and 10 to 20% by weight, 
<!-- EPO <DP n="37"/>-->
 relative to the weight of the pharmaceutical composition, of at least one further compound selected from the group consisting of mannitol, calcium hydrogen phosphate, lactose and starch. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. A pharmaceutical composition according to claim 9, wherein </claim-text><claim-text> the binder is selected from the group consisting of polyvinyl pyrrolidone, </claim-text><claim-text> hydroxypropylmethylcellulose and combinations thereof; </claim-text><claim-text> the disintegrant is selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </claim-text><claim-text> the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </claim-text><claim-text> the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1 . A pharmaceutical composition according to claim 10 comprising </claim-text><claim-text> 30 to 60% by weight, relative to the weight of the pharmaceutical composition, of lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof; 1 to 20% by weight, relative to the weight of the pharmaceutical composition, of a binder selected from the group consisting of polyvinyl pyrrolidone, </claim-text><claim-text> hydroxypropylmethylcellulose and combinations thereof; </claim-text><claim-text> 0.5 to 8% by weight, relative to the weight of the pharmaceutical composition, of a disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium and combinations thereof; </claim-text><claim-text> 0.01 to 3% by weight, relative to the weight of the pharmaceutical composition, of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, magnesium behenate, calcium behenate, magnesium arachinate, calcium arachinate and combinations thereof; </claim-text><claim-text> a filler which comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the weight of the pharmaceutical composition, and lactose in an amount of 10 to 20% by weight, relative to the weight of the pharmaceutical composition. 
<!-- EPO <DP n="38"/>-->
</claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. A pharmaceutical composition according to any of claims 1 to 1 1 wherein the microcrystalline cellulose has a median particle size of 50 to 100 μηι. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. A pharmaceutical composition according to any of claims 1 to 12 which is a tablet or a coated tablet. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. Process for producing the pharmaceutical composition according to any of claims 1 to 13 comprising </claim-text><claim-text> (a) granulating a mixture comprising lapatinib or a pharmaceutically acceptable salt or solvate or solvated salt thereof, the filler, and optionally the disintegrant, using an aqueous solution of the binder as granulation liquid; </claim-text><claim-text> (b) drying the granules obtained in step (a); </claim-text><claim-text> (c) mixing the dried granules with the lubricant, and optionally the disintegrant; </claim-text><claim-text> provided that the disintegrant is added in step (a) and/or (c). </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. Process according to claim 14 wherein the granules are dried to a water content of 0.5 to 3% by weight. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
